Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2018

View Archived Issues

Sleep is depression's opposite

Novel CRISPR/Cas-mediated rat model of idiosyncratic drug-induced liver injury

First-in-human data presented for AB-023

Aspirin increases lysosomal biogenesis via PPARalpha and decreases amyloid plaque pathology in mice

Motile sperm domain-containing protein 2 promotes breast cancer cell migration and metastasis

Estrogen receptor alpha activation depends on fibronectin-beta1-integrin pathway in breast cancer

Bench and bedside: Phosphatase inhibition sheds ugly duckling status with new platform technology

Beta Cat studies BC-2059 for unresectable desmoid tumors in phase I

Primary endpoints met in phase IIb study of PRX for presbyopia

Phase III study of RHB-104 in Crohn's disease meets primary endpoint

Regenera initiates phase II study of RPh-201 in NAION

Dong-A conducts phase II study with DA-8010 in overactive bladder

First-in-human study investigates CALR exon 9 mutant peptide vaccine in CALR-mutant MPNs

Janssen studies PRMT5 inhibitor JNJ-64619178 in advanced cancers

FDA approves Azedra for pheochromocytoma or paraganglioma

Arcus cleared to begin phase I trial of anti-TIGIT antibody AB-154

Stop-gain variant in GMIP gene tied to Alzheimer's disease pathogenesis

Contactin-2 levels are altered in mild cognitive impairment

ASTRAL-1 study of guadecitabine in AML does not meet coprimary endpoints

Immutep to begin phase II study of eftilagimod alfa with pembrolizumab

Regeneus reports promising first-in-human data for autologous tumor vaccine RGSH-4-K

Phase II study of laquinimod in Huntington's disease does not meet primary endpoint

European Commission approves Aimovig to prevent migraines

HSP27 found as a potential therapeutic target for treating VCID

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...